Sarepta Therapeutics, Inc. (NASDAQ:SRPT).
On September 20 the stock rating was upgraded from “” to “Outperform” by Cowen & Co.. On September 19 the company was changed to a “Neutral” according to a SunTrust Robinson Humphrey report which is up from the previous “Perform” rating.
On September 19 the company was upgraded to “Hold” from “Underperform” with a current price target of $50.00 by analysts at Jefferies. On September 19, 2016 the stock rating was rated “Buy” in a report from Janney Capital a boost from the previous “Neutral” rating.
On September 19 the company was upgraded from “” to “Outperform” and a price target of $88.00 was set in a report from PiperJaffray.
In the market the company is trading down since yesterday’s close of $59.66. Shares are trading at $59.10 just a bit higher than the 50 day moving average which is $32.78 and which is slightly above the 200 day moving average of $22.96. The 50 day moving average was up by +80.27% and the 200 day average went up by +157.40%.
In the last earnings report the EPS was $-5.36 and is estimated to be $-4.17 for the current year with 47,899,000 shares presently outstanding. Next quarter’s EPS is expected be $-0.26 with next year’s EPS projected to be $-1.47.
Investors are more bullish on shares of the company recently as indicated by the downtick in short interest. The stock saw a fall in short interest of -0.03% as of September 15, 2016 from the last reporting period. Short interest decreased 516,994 over that period. Days to cover decreased from 8.3 to 4.1 and the short interest percentage is 0.30% as of September 15.